The FDA approves Avastin in combination with chemotherapy for patients with platinum-resistant recurrent ovarian cancer, based on results of the phase 3 AURELIA trial. The Food and Drug Administration ...

Update 4:06 p.m.: A panel advising the Food and Drug Administration voted against an appeal by Genentech to preserve the approval of Avastin as a treatment for advanced breast cancer. In unanimous ...

A panel of cancer experts has ruled for a second time that Avastin, the best-selling cancer drug in the world, should no longer be used in breast cancer patients, clearing the way for the U.S.

(CBS News) Back in February, the FDA issued a warning about vials of a popular cancer drug that turned out to be fakes. The vials labeled "Avastin" contained a liquid that was worthless. Who would ...

A panel of cancer experts has ruled for a second time that Avastin, the best-selling cancer drug in the world, should no longer be used in breast-cancer patients, clearing the way for the government ...

WASHINGTON, June 30 (Reuters) - Medicare will continue paying for Roche Holding's drug Avastin for breast cancer, regardless of what health regulators decide about the medicine's future, a spokesman ...

Avastin is an angiogenesis inhibitor, meaning it cuts off the independent blood supply that a tumor develops to feed and oxygenate itself. A molecularly targeted therapy, Avastin neutralizes vascular ...

Surprising results from two new studies may reopen debate about the value of Avastin for breast cancer. The drug helped make tumors disappear in certain women with early-stage disease, researchers ...

First, some background. In 2004, the FDA approved Avastin for first-line treatment of patients with metastatic, or malignant, colorectal cancer. The tremendous success of Avastin turned Genentech from ...

Avastin (bevacizumab), a monoclonal antibody that inhibits the vascular endothelial growth factor and prevents the growth of blood vessels (angiogenesis), has received FDA approval to treat patients ...

Cancer-fighter Avastin just came up short as a treatment for ovarian tumors. Two studies found that the drug, which blocks the formation of new blood vessels, didn't extend the lives of patients with ...

The evidence for avastin versus lucentis is weak for one very simple reason: the company refused to license it. Whether this was because of cock-up or conspiracy does not matter. Cock-up in that Roche ...